Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 7/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5129226 | 0.83 | MGLL (0.50) | MGLLRETCNR1DGAT1FAAH | |
| SCHEMBL5130065 | 0.83 | MGLL (0.50) | MGLLCNR1DGAT1FAAHTRPV1 | |
| SCHEMBL5123680 | 0.77 | MGLL (0.50) | MGLLCNR1DGAT1TRPV1 | |
| SCHEMBL5116242 | 0.77 | TRPV1 (0.63) | RETKITKDRFLT3TRPV1 | |
| SCHEMBL5123741 | 0.71 | TRPV1 (0.58) | MGLLCNR1TRPV1 | |
| SCHEMBL2734510 | 0.70 | TRPV1 (0.57) | MGLLCNR1DGAT1TRPV1 | |
| SCHEMBL2734355 | 0.69 | TRPV1 (0.61) | MGLLCNR1TRPV1 | |
| SCHEMBL206358 | 0.69 | TRPV1 (0.58) | MGLLCNR1DGAT1TRPV1 | |
| SCHEMBL2734509 | 0.67 | TRPV1 (0.64) | CNR1TRPV1 | |
| SCHEMBL206493 | 0.67 | TRPV1 (0.56) | MGLLDGAT1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045546-A1 | Tetradydro-Naphthalene And Urea Derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1678123-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | Bayer HealthCare AG (DE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005040100-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045546-A1 | Tetradydro-Naphthalene And Urea Derivatives | NMUR1, GPR17, NMUR2 | MGLL 4480/4885RET 686/4885CNR1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.